1. Home
  2. KRYS vs GBDC Comparison

KRYS vs GBDC Comparison

Compare KRYS & GBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KRYS
  • GBDC
  • Stock Information
  • Founded
  • KRYS 2015
  • GBDC 2009
  • Country
  • KRYS United States
  • GBDC United States
  • Employees
  • KRYS N/A
  • GBDC N/A
  • Industry
  • KRYS Biotechnology: Biological Products (No Diagnostic Substances)
  • GBDC Finance: Consumer Services
  • Sector
  • KRYS Health Care
  • GBDC Finance
  • Exchange
  • KRYS Nasdaq
  • GBDC Nasdaq
  • Market Cap
  • KRYS 4.5B
  • GBDC 4.0B
  • IPO Year
  • KRYS 2017
  • GBDC 2010
  • Fundamental
  • Price
  • KRYS $148.39
  • GBDC $15.40
  • Analyst Decision
  • KRYS Strong Buy
  • GBDC Buy
  • Analyst Count
  • KRYS 7
  • GBDC 6
  • Target Price
  • KRYS $206.67
  • GBDC $16.25
  • AVG Volume (30 Days)
  • KRYS 292.3K
  • GBDC 1.2M
  • Earning Date
  • KRYS 02-24-2025
  • GBDC 02-04-2025
  • Dividend Yield
  • KRYS N/A
  • GBDC 10.13%
  • EPS Growth
  • KRYS N/A
  • GBDC N/A
  • EPS
  • KRYS 1.77
  • GBDC 1.36
  • Revenue
  • KRYS $241,519,000.00
  • GBDC $724,677,000.00
  • Revenue This Year
  • KRYS $485.65
  • GBDC $23.90
  • Revenue Next Year
  • KRYS $58.64
  • GBDC N/A
  • P/E Ratio
  • KRYS $83.69
  • GBDC $11.32
  • Revenue Growth
  • KRYS 2722.80
  • GBDC 20.16
  • 52 Week Low
  • KRYS $107.50
  • GBDC $14.05
  • 52 Week High
  • KRYS $219.34
  • GBDC $17.72
  • Technical
  • Relative Strength Index (RSI)
  • KRYS 37.81
  • GBDC 58.22
  • Support Level
  • KRYS $141.72
  • GBDC $15.18
  • Resistance Level
  • KRYS $152.94
  • GBDC $15.41
  • Average True Range (ATR)
  • KRYS 5.22
  • GBDC 0.17
  • MACD
  • KRYS -0.42
  • GBDC 0.04
  • Stochastic Oscillator
  • KRYS 33.00
  • GBDC 96.77

About KRYS Krystal Biotech Inc.

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

About GBDC Golub Capital BDC Inc.

Golub Capital BDC Inc is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to generate current income and capital appreciation by investing in senior secured and one-stop loans in United States middle-market companies. It also invests in the second lien and subordinated loans, warrants, and minority equity securities in United States middle-market companies. The company generally invests in securities that have been rated below investment grade by independent rating agencies or that would be rated below investment grade if rated. Maximum investment is done in USA and Canadian Companies, with maximum profit earned from those countries.

Share on Social Networks: